A recent study found that antiretroviral therapy adherence below 90% was associated with significantly lower odds of viral suppression among women living with HIV.

“With the chronic nature of HIV and the risk of resistance, supporting patients in overcoming the challenges that accompany long-term medication adherence through cotailored approaches should remain a priority when providing care to women living with HIV,” the authors wrote.

The study was led by Alexandra de Pokomandy, Department of Family Medicine, McGill University, Montreal, Quebec, Canada. It was published online on May 2, 2025, in HIV Medicine.

The study was limited by a small sample size in groups with lower adherence, which may have reduced the statistical power to detect significant differences. All measures were self-reported, introducing social desirability bias and recall bias. The study also lacked information on the status of mental health treatment and the duration of viral suppression. 

The study received funding from the Canadian Institutes of Health Research, the Canadian HIV Trials Network, the Ontario HIV Treatment Network, and the Ontario Academic Health Science Centers Alternative Funding Plans Innovation. Two authors reported having financial ties with several pharmaceutical companies. 

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.